Download Free Sample
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthc.....
VEGF Market: Competitive Landscape, Pipeline, and Market Analysis 2023
VEGF Market: Competitive Landscape, Pipeline, and Market Analysis 2023
VEGF (Vascular Endothelial Growth Factor) is a protein that plays a crucial role in angiogenesis, and the formation of new blood vessels. It is primarily secreted by cells in response to tissue hypoxia and triggers a cascade of events that stimulate the growth of new blood vessels. By binding to its receptors on endothelial cells, VEGF promotes endothelial cell proliferation, migration, and permeability, facilitating the development of new blood vessels. In medicine, VEGF inhibitors are used to target and inhibit the activity of VEGF, thereby suppressing angiogenesis and reducing blood vessel growth. VEGF-based therapies are utilized in the treatment of several disease indications, including age-related macular degeneration (AMD), diabetic retinopathy (DR), and various types of cancer such as colorectal, lung, and renal cell carcinoma. According to the World Health Organization (WHO), AMD is a leading cause of vision loss, affecting over 170 million people globally. In Europe, the prevalence of AMD is estimated to be around 7.3% among individuals aged 65 years and older. Diabetic retinopathy, a common complication of diabetes, affects approximately one-third of individuals with diabetes globally.
In the United States, it is reported that over 30 million people have diabetes, and diabetic retinopathy accounts for a significant proportion of vision loss and blindness among working-age adults. The incidence and prevalence of cancer vary across specific types and regions. For instance, colorectal cancer is the third most commonly diagnosed cancer worldwide, with approximately 1.8 million new cases reported in Europe and the United States combined. Companies such as Roche, Pfizer, HLB Bio Group, Novartis, Bayer, Eli Lilly, Sanofi, AstraZeneca, Simcere, Takeda, Bausch Health, Novartis, Outlook Therapy, Tactical Therapy, GeneScience, J&J, Komipharm, Biocon, Herantis, Celltrion, Dr. Reddy's, Sino Biopharm cater to this category. Moreover, many companies are coming up with new molecules in this space. For instance, GSK is currently conducting a clinical trial of the SU5416 for treating adenocarcinoma.
Key Developments:
Approved VEGF Molecules
VEGF Pipeline Molecules
Clinical Activity and Development of VEGF
In the VEGF space, more than 20 companies are conducting more than 300 clinical trials in this category of drugs. For instance,
|
Product Name |
Total Studies |
|
Dovitinib (TKI258) |
60 |
|
Famitinib (SHR 1020) |
52 |
|
Vatalanib (PTK787) |
43 |
|
Sitravatinib (MGCD516) |
37 |
|
Semaxanib (SU5416) |
31 |
|
Brivanib alaninate (BMS-582664) |
28 |
|
lucitanib (E 3810) |
27 |
|
Motesanib (AMG 706) |
26 |
|
Vorolanib (X-82) |
22 |
|
Ivonescimab (AK112) |
21 |
|
Linifanib (ABT-869) |
20 |
|
Vadimezan (ASA404) |
20 |
|
Thrombospondin-1 mimetic (ABT-510) |
17 |
|
Chiauranib (CS 2164) |
16 |
|
Simtuzumab (GS 6624) |
15 |
|
Tesevatinib (KD019) |
15 |
|
Foretinib (GSK1363089) |
11 |
|
RGX-314 |
9 |
|
VEGFR1-1084 |
9 |
|
BI 836880 |
8 |
VEGF (Vascular Endothelial Growth Factor) is a target indication in the field of medicine that plays a crucial role in angiogenesis, and the formation of new blood vessels. By targeting VEGF, pharmaceutical interventions aim to treat various conditions and diseases associated with abnormal blood vessel growth, such as age-related macular degeneration, diabetic retinopathy, and certain types of cancers like colorectal, lung, and renal cell carcinoma. VEGF inhibitors, including monoclonal antibodies and tyrosine kinase inhibitors, are designed to inhibit VEGF signaling pathways, thereby reducing the formation of new blood vessels, inhibiting tumor growth, and potentially improving patient outcomes in these specific indications.
The global VEGF market is segmented into the United States, United Kingdom, Germany, Spain, France, Italy, and Japan. The overall regional market analysis of VEGF in the US indicates a significant market presence and growth potential. The US market for VEGF-based therapies is well-established and highly competitive, driven by factors such as a large patient population, advanced healthcare infrastructure, and strong investment in research and development. The market is primarily dominated by established pharmaceutical companies that offer VEGF inhibitors and other related therapies. Furthermore, the increasing prevalence of diseases like age-related macular degeneration, diabetic retinopathy, and various cancers fuels the demand for VEGF-targeted interventions, contributing to market growth. The growth drivers of the VEGF market encompass several factors. Firstly, advancements in understanding the role of VEGF in angiogenesis and tumor progression have led to increased research and development activities focused on VEGF inhibitors and related therapies. Canada, on the other hand, is known for its well-established healthcare system and supportive regulatory framework, making it an attractive market for VEGFs. These countries are increasingly adopting VEGFs due to their efficacy and potential to improve patient outcomes. On the other hand, the VEGF market in Europe has witnessed significant growth in recent years. Major countries driving this market include Germany, France, Italy, and Spain. These countries have a robust pharmaceutical industry, which is a key driver for the VEGF market.
Latin America
Europe
Asia Pacific
Middle East
North America
Download Free Sample Report
VEGF drugs are used in the management of age-related macular degeneration (AMD), diabetic retinopathy (DR), and various types of cancer such as colorectal, lung, and renal cell carcinoma.
The growth drivers of the VEGF market encompass several factors. Firstly, advancements in understanding the role of VEGF in angiogenesis and tumor progression have led to increased research and development activities focused on VEGF inhibitors and related therapies.
The major players in this space are Roche, Pfizer, HLB Bio Group, Novartis, Bayer, Eli Lilly, Sanofi, AstraZeneca, Simcere, Takeda, Bausch Health, Novartis, Outlook Therapy, Tactical Therapy, GeneScience, J&J, Komipharm, Biocon, Herantis, Celltrion, Dr. Reddy's, Sino Biopharm.
Despite favorable market conditions, the VEGF drug market faces certain restraints. One major challenge is the high cost of VEGF inhibitors, which can limit access for patients and strain healthcare budgets. Additionally, the potential side effects and toxicity associated with VEGF inhibitors pose concerns for both patients and healthcare providers, requiring careful monitoring and management during treatment.
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.